Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast

Diagnostics & Research is Zen Rated C and is the 69th ranked industry out of 146 stock market industries

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
CDNA	CAREDX INC	$1.49B	$28.76	$24.50	-14.81%	Buy	2	9.51%	N/A	25.48%	19.43%
SHC	SOTERA HEALTH CO	$5.18B	$18.17	$21.00	15.58%	Strong Buy	4	5.75%	42.30%	58.30%	11.21%
BLLN	BILLIONTOONE INC	$5.67B	$123.25	$117.50	-4.67%	Strong Buy	4	N/A	N/A	N/A	N/A
NEO	NEOGENOMICS INC	$1.84B	$14.11	$15.60	10.56%	Strong Buy	5	9.27%	N/A	9.84%	6.06%
LH	LABCORP HOLDINGS INC	$22.69B	$276.68	$317.60	14.79%	Buy	5	5.57%	23.87%	21.54%	9.85%
ILMN	ILLUMINA INC	$28.75B	$190.05	$167.50	-11.87%	Buy	10	6.06%	7.80%	45.66%	18.63%
A	AGILENT TECHNOLOGIES INC	$37.86B	$134.04	$155.36	15.91%	Strong Buy	11	5.21%	14.06%	34.64%	18.88%
NEOG	NEOGEN CORP	$2.10B	$9.65	N/A	N/A	N/A	N/A	-0.20%	N/A	4.86%	3.04%
WAT	WATERS CORP	$36.64B	$373.22	$400.00	7.18%	Buy	15	26.68%	32.54%	13.78%	8.59%
DGX	QUEST DIAGNOSTICS INC	$22.95B	$207.35	$224.00	8.03%	Buy	9	4.92%	11.83%	21.42%	9.47%
DHR	DANAHER CORP	$141.67B	$200.16	$219.75	9.79%	Strong Buy	12	5.67%	24.71%	16.33%	10.35%
IQV	IQVIA HOLDINGS INC	$34.64B	$207.55	$222.54	7.22%	Strong Buy	13	5.49%	25.01%	48.51%	10.17%
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$11.07B	$229.75	$220.44	-4.05%	Buy	9	0.89%	N/A	23.80%	9.05%
IDXX	IDEXX LABORATORIES INC	$44.51B	$564.21	$719.17	27.46%	Buy	6	8.53%	11.47%	108.33%	49.79%
MEDP	MEDPACE HOLDINGS INC	$15.14B	$530.19	$491.67	-7.27%	Hold	9	7.17%	9.31%	112.62%	31.64%
BDSX	BIODESIX INC	$216.53M	$21.42	$28.33	32.27%	Strong Buy	3	18.76%	N/A	-118.55%	-11.44%
RVTY	REVVITY INC	$12.40B	$111.11	$108.64	-2.23%	Hold	11	3.73%	46.62%	11.43%	6.84%
LAB	STANDARD BIOTOOLS INC	$331.42M	$0.85	N/A	N/A	N/A	N/A	0.87%	N/A	N/A	N/A
ICLR	ICON PLC	$12.72B	$166.10	$176.00	5.96%	Buy	12	2.32%	33.55%	12.37%	7.05%
TMO	THERMO FISHER SCIENTIFIC INC	$196.41B	$528.51	$592.91	12.19%	Buy	11	6.00%	18.49%	24.70%	11.32%
MTD	METTLER TOLEDO INTERNATIONAL INC	$26.26B	$1,299.53	$1.36k	5.03%	Buy	8	4.74%	10.32%	-3,111.10%	35.52%
PRPO	PRECIPIO INC	$42.90M	$24.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MYGN	MYRIAD GENETICS INC	$553.47M	$5.86	$5.83	-0.46%	Hold	3	5.92%	N/A	16.28%	8.15%
NTRA	NATERA INC	$39.08B	$272.89	$272.25	-0.23%	Strong Buy	12	17.42%	N/A	24.85%	16.86%
GH	GUARDANT HEALTH INC	$21.00B	$158.40	$159.05	0.41%	Strong Buy	21	27.72%	N/A	-290.96%	27.51%
BNR	BURNING ROCK BIOTECH LTD	$112.14M	$10.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QGEN	QIAGEN NV	$8.57B	$41.44	$42.00	1.35%	Buy	8	4.85%	15.61%	19.45%	11.21%
TWST	TWIST BIOSCIENCE CORP	$5.63B	$90.35	$87.88	-2.74%	Strong Buy	8	14.37%	N/A	23.59%	15.87%
QUCY	QUANTUM CYBER NV	$18.47M	$1.26	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ACRS	ACLARIS THERAPEUTICS INC	$768.15M	$5.50	$11.80	114.55%	Strong Buy	5	-10.88%	N/A	-87.46%	-63.23%
OPK	OPKO HEALTH INC	$928.76M	$1.23	$1.50	21.95%	Buy	1	1.58%	N/A	N/A	N/A
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$148.21M	$4.59	$12.00	161.44%	Strong Buy	1	153.67%	N/A	N/A	N/A
RDNT	RADNET INC	$4.98B	$63.31	$65.00	2.67%	Strong Buy	1	14.96%	N/A	9.04%	2.51%
GRAL	GRAIL INC	$3.08B	$71.80	$67.50	-5.99%	Buy	8	22.80%	N/A	-18.88%	-16.84%
PRE	PRENETICS GLOBAL LTD	$317.23M	$18.68	$29.50	57.92%	Strong Buy	2	84.01%	N/A	-7.26%	-5.01%
XGN	EXAGEN INC	$100.02M	$4.14	$8.86	113.94%	Strong Buy	7	9.41%	N/A	6.76%	1.88%
STIM	NEURONETICS INC	$124.56M	$1.79	$3.00	67.60%	Strong Buy	1	9.85%	N/A	-160.53%	-16.98%
BIAF	BIOAFFINITY TECHNOLOGIES INC	$3.17M	$0.70	N/A	N/A	N/A	N/A	N/A	N/A	-1,023.31%	-471.57%
CSTL	CASTLE BIOSCIENCES INC	$696.98M	$22.98	$42.00	82.77%	Strong Buy	5	9.28%	N/A	2.15%	1.81%
FLGT	FULGENT GENETICS INC	$579.94M	$20.42	$15.00	-26.54%	Hold	1	12.43%	N/A	-4.15%	-3.77%
PSNL	PERSONALIS INC	$1.58B	$15.04	$12.25	-18.55%	Strong Buy	4	34.24%	N/A	-24.32%	-19.04%
VNRX	VOLITIONRX LTD	$10.83M	$1.30	$28.00	2,053.85%	Strong Buy	3	122.21%	N/A	-15.94%	56.42%
ISPC	ISPECIMEN INC	$3.36M	$2.34	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DRIO	DARIOHEALTH CORP	$48.99M	$6.70	$10.50	56.72%	Buy	2	36.34%	N/A	10.88%	6.57%
SERA	SERA PROGNOSTICS INC	$75.18M	$1.92	$6.00	212.50%	Buy	1	435.41%	N/A	-33.67%	-24.34%
NDRA	ENDRA LIFE SCIENCES INC	$6.99M	$5.50	$25.00	354.55%	Buy	1	N/A	N/A	-220.40%	-114.54%
BNBX	BNB PLUS CORP	$1.17M	$0.16	N/A	N/A	N/A	N/A	N/A	N/A	-4,843.03%	-4,441.90%
ADVB	ADVANCED BIOMED INC	$7.05M	$5.10	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBAI	CHECK-CAP LTD	$7.93M	$1.13	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDXH	MDXHEALTH SA	$2.21M	$0.43	$3.50	713.95%	Strong Buy	3	7.92%	N/A	N/A	N/A
XWEL	XWELL INC	$7.94M	$0.94	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRIB	TRINITY BIOTECH PLC	$6.64M	$0.36	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-177.84%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Jul 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Caredx (NASDAQ:CDNA)

Caredx (NASDAQ:CDNA) is the #1 top diagnostic & research stock out of 52 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Caredx (NASDAQ:CDNA) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.

Caredx (NASDAQ:CDNA) has a Due Diligence Score of 34, which is 7 points higher than the diagnostic & research industry average of 27.

CDNA passed 11 out of 33 due diligence checks and has average fundamentals. Caredx has seen its stock return 43.66% over the past year, overperforming other diagnostic & research stocks by 20 percentage points.

Caredx has an average 1 year price target of $24.50, a downside of -14.81% from Caredx's current stock price of $28.76.

Caredx stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Caredx, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 52 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: B, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 35, which is 8 points higher than the diagnostic & research industry average of 27.

SHC passed 12 out of 33 due diligence checks and has average fundamentals. Sotera Health Co has seen its stock return 56.5% over the past year, overperforming other diagnostic & research stocks by 33 percentage points.

Sotera Health Co has an average 1 year price target of $21.00, an upside of 15.58% from Sotera Health Co's current stock price of $18.17.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Sotera Health Co, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Billiontoone (NASDAQ:BLLN)

Billiontoone (NASDAQ:BLLN) is the #3 top diagnostic & research stock out of 52 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Billiontoone (NASDAQ:BLLN) is: Value: C, Growth: B, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: C.

Billiontoone (NASDAQ:BLLN) has a Due Diligence Score of 11, which is -16 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates BLLN as a "B".

BLLN passed 3 out of 33 due diligence checks and has weak fundamentals.

Billiontoone has an average 1 year price target of $117.50, a downside of -4.67% from Billiontoone's current stock price of $123.25.

Billiontoone stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Billiontoone, 75% have issued a Strong Buy rating, 0% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 5.53%, which is 4 percentage points higher than the diagnostic & research industry average of 1.46%.

Qiagen Nv's dividend payout ratio of 142.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.6%, which is the same as the diagnostic & research industry average of 1.46%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 35.6% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.04%, which is the same as the diagnostic & research industry average of 1.46%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 25.4% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.31% in the last day, and down -1.26% over the last week. Bnb Plus was the among the top losers in the diagnostics & research industry, dropping -57.11% yesterday.

BNB Plus shares are trading lower after the company announced it received a Nasdaq delisitng notification.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 14, which is 4 points higher than the diagnostic & research industry average of 10. It passed 1 out of 7 valuation due diligence checks.

Qiagen Nv's stock has dropped -14.17% in the past year. It has underperformed other stocks in the diagnostic & research industry by -38 percentage points.

2. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Agilent Technologies has a valuation score of 0, which is -10 points higher than the diagnostic & research industry average of 10. It passed 0 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates A a Valuation Rating of "B".

Agilent Technologies's stock has gained 11.63% in the past year. It has underperformed other stocks in the diagnostic & research industry by -12 percentage points.

3. Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific (NYSE:TMO) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Thermo Fisher Scientific has a valuation score of 14, which is 4 points higher than the diagnostic & research industry average of 10. It passed 1 out of 7 valuation due diligence checks.

Thermo Fisher Scientific's stock has gained 24.26% in the past year. It has overperformed other stocks in the diagnostic & research industry by 1 percentage points.

Are diagnostic & research stocks a good buy now?

50% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 7.57% over the next year.

2.33% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 16.28% of diagnostic & research stocks are rated B (Buy), 67.44% are rated C (Hold), 13.95% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 14.2x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Diagnostic & Research Stocks FAQ

1. Caredx (NASDAQ:CDNA)

2. Sotera Health Co (NASDAQ:SHC)

3. Billiontoone (NASDAQ:BLLN)

1. Qiagen Nv (NYSE:QGEN)

2. Quest Diagnostics (NYSE:DGX)

3. Labcorp Holdings (NYSE:LH)

1. Qiagen Nv (NYSE:QGEN)

2. Agilent Technologies (NYSE:A)

3. Thermo Fisher Scientific (NYSE:TMO)

Company

Stock Tools

Stock Ideas